WNT5A has been associated with increased resistance to chemotherapeutics in ovarian and breast cancer cells (Peng et al., 2011; Hung et al., 2014), and approaches of directly targeting WNT5A-mediated signaling for cancer therapy have been proposed for prostate cancer (Gao et al., 2022), small cell lung cancer (Kim et al., 2022) and melanoma (Jenei et al., 2009). The gene discussed is WNT5A; the disease is small cell lung carcinoma.